New Drugs in Cancer Chemotherapy

Nonfiction, Health & Well Being, Medical, Medical Science, Pharmacology, Specialties, Oncology
Cover of the book New Drugs in Cancer Chemotherapy by , Springer Berlin Heidelberg
View on Amazon View on AbeBooks View on Kobo View on B.Depository View on eBay View on Walmart
Author: ISBN: 9783642815652
Publisher: Springer Berlin Heidelberg Publication: March 9, 2013
Imprint: Springer Language: English
Author:
ISBN: 9783642815652
Publisher: Springer Berlin Heidelberg
Publication: March 9, 2013
Imprint: Springer
Language: English

The Analog Potential in Cancer Chemotherapy in the United States and Japan S. K. Carter Northern California Cancer Program, 1801 Page Mill Road, Building B, Suite 200, USA - Palo Alto, CA 94304 The bilateral collaborative program in cancer research between Japan and the United States is one of the oldest programs of this type. It is sponsored in the United States by the National Cancer Institute [1], while in Japan the sponsoring organization is the Japan Society for the Promotion of Science. Annual symposia concerning treatment have been held and in recent years they have been published [2, 3]. Drug development in both Japan and the United States has evolved over the years to an increasing emphasis on second generation compounds. This has come about as a result of the initial successes of chemotherapy development. Many active structures have been uncovered and the armamentarium of the medical and pediatric oncologist has grown dramatically. The uncovering of an active structure provides an opportunity for analog synthesis and attempts at elucidating structure-activity relationships. It is hoped that the therapeutic index of active structures can be improved so as to achieve superior clinical results.

View on Amazon View on AbeBooks View on Kobo View on B.Depository View on eBay View on Walmart

The Analog Potential in Cancer Chemotherapy in the United States and Japan S. K. Carter Northern California Cancer Program, 1801 Page Mill Road, Building B, Suite 200, USA - Palo Alto, CA 94304 The bilateral collaborative program in cancer research between Japan and the United States is one of the oldest programs of this type. It is sponsored in the United States by the National Cancer Institute [1], while in Japan the sponsoring organization is the Japan Society for the Promotion of Science. Annual symposia concerning treatment have been held and in recent years they have been published [2, 3]. Drug development in both Japan and the United States has evolved over the years to an increasing emphasis on second generation compounds. This has come about as a result of the initial successes of chemotherapy development. Many active structures have been uncovered and the armamentarium of the medical and pediatric oncologist has grown dramatically. The uncovering of an active structure provides an opportunity for analog synthesis and attempts at elucidating structure-activity relationships. It is hoped that the therapeutic index of active structures can be improved so as to achieve superior clinical results.

More books from Springer Berlin Heidelberg

Cover of the book Apoptosis: Biology and Mechanisms by
Cover of the book Air Instrument Surgery by
Cover of the book Medical Retina by
Cover of the book Clean-up of Former Soviet Military Installations by
Cover of the book Wissenschaft auf Safari by
Cover of the book Contradictions by
Cover of the book Dynamics in Logistics by
Cover of the book Modeling and Managing Shallow Lake Eutrophication by
Cover of the book Plant Transposable Elements by
Cover of the book Spontaneous Symmetry Breaking, Self-Trapping, and Josephson Oscillations by
Cover of the book Das Glück des Traurigseins by
Cover of the book Patientenorientierte Beratung in der Pflege by
Cover of the book Radioactivity Transfer in Environment and Food by
Cover of the book Endoscopy of the Paranasal Sinuses by
Cover of the book Molecular Organometallic Materials for Optics by
We use our own "cookies" and third party cookies to improve services and to see statistical information. By using this website, you agree to our Privacy Policy